NHS rejects ketamine for depression as psychiatrists accuse NICE of mental health discrimination

Spravato (pictured), a nasal spray also known as esketamine, got the green light from the European Medicines Agency in December 2019 as a fast-acting treatment for depression sufferers.
* This article was originally published here
Comments
Post a Comment